Skip to main content
Premium Trial:

Request an Annual Quote

Patents Held by Benitec, Collaborator Allowed in US, South Korea, China


Benitec Biopharma said this week that the US Patent and Trademark Office has granted a patent from the company’s core Graham intellectual property portfolio.

Additionally, the company said it has received a South Korean patent related to its lead hepatitis C drug candidate TT-034, while a collaborator on its non-small cell lung cancer program has been issued a patent related to the use of RNAi to sensitize treatment-resistant lung cancer cells.

The US patent application, No. 20120135517, is entitled “Methods and Means for Obtaining Modified Phenotypes,” and claims DNA constructs targeting multiple genes with a broader range of length limitations on the sequence than in earlier patents, Benitec said. The constructs can also be used in a range of cells, including potentially stem cells.

The South Korean patent, which is owned by Benitec, is entitled “Multiple Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents,” the company noted.

The Chinese patent was issued to the University of New South Wales, and is entitled “Methods for Detecting and Modulating the Sensitivity of Tumor Cells to Anti-Mitotic Agents.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.